Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 22 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Visser, Pieter Jelle [Clear All Filters]
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia..
JAMA Psychiatry. 75(1), 84-95.
(2018). Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline..
Alzheimers Res Ther. 10(1), 56.
(2018). Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers..
J Alzheimers Dis.
(2018). Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease..
Alzheimers Dement. 14(7), 913-924.
(2018). Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI)..
Neurobiol Aging. 53, 1-10.
(2017). Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study..
J Alzheimers Dis. 60(4), 1387-1395.
(2017). Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline..
Alzheimers Res Ther. 9(1), 101.
(2017). Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes..
J Alzheimers Dis. 56(2), 543-555.
(2017). Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study..
J Alzheimers Dis. 60(3), 1119-1128.
(2017). Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers..
Alzheimers Dement. 13(8), 903-912.
(2017). Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition..
J Alzheimers Dis. 60(3), 1025-1034.
(2017). MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study..
Curr Alzheimer Res. 13(12), 1407-1413.
(2016).
(2016). Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis..
JAMA. 313(19), 1924-38.
(2015). Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment..
Neurobiol Aging. 34(8), 2003-13.
(2013). Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI..
Neurology. 80(12), 1124-32.
(2013). Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study..
Dement Geriatr Cogn Disord. 36(1-2), 1-19.
(2013). Association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent..
Neurobiol Aging. 33(1), 201.e1-8.
(2012). Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI..
Neurobiol Aging. 33(10), 2272-81.
(2012).
(2011).
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment..
JAMA. 302(4), 385-93.
(2009).
(2009).